(Q56786381)

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

In vitro sensitivity of human herpesvirus-6 to antiviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

Inhibition of human herpesvirus 6 replication by 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (2HM-HBG) and other antiviral compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

6-[2-phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines: a new class of acyclic pyrimidine nucleoside phosphonates with antiviral activity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

Identification and some properties of a unique DNA polymerase from cells infected with human B-lymphotropic virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

Potent, selective and cell-mediated inhibition of human herpesvirus 6 at an early stage of viral replication by the non-nucleoside compound CMV423.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

Human herpesvirus 6 DNA polymerase: enzymatic parameters, sensitivity to ganciclovir and determination of the role of the A961V mutation in HHV-6 ganciclovir resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

Role of the human herpesvirus 6 u69-encoded kinase in the phosphorylation of ganciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

Update on human herpesvirus 6 biology, clinical features, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

Quantitative analysis of human herpesvirus 6 cell tropism

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

New inhibitors of human cytomegalovirus (HCMV) on the horizon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

A randomized clinical trial of valacyclovir in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

Disruption of the interactions between the subunits of herpesvirus DNA polymerases as a novel antiviral strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

Susceptibility of human herpesvirus 6 to antiviral compounds by flow cytometry analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

Selection of the same mutation in the U69 protein kinase gene of human herpesvirus-6 after prolonged exposure to ganciclovir in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

Anti-herpesvirus activity of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl)-cycloprop-1'-yl]methyl] x guanine (A-5021) in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

Antiviral activity of selected acyclic nucleoside analogues against human herpesvirus 6.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

Mapping ganciclovir resistance in the human herpesvirus-6 U69 protein kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

Cyclin-dependent kinases as cellular targets for antiviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

Factors affecting delivery of antiviral drugs to the brain

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

Comparison of antiviral compounds against human herpesvirus 6 and 7.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021

Human herpesvirus 6 infection in hematopoietic stem cell transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-7069%2806%2912023-6

7 January 2021